JP6266012B2 - 改変抗ＩＬ−２３ｐ１９抗体の溶液製剤 - Google Patents

改変抗ＩＬ−２３ｐ１９抗体の溶液製剤 Download PDF

Info

Publication number
JP6266012B2
JP6266012B2 JP2015547448A JP2015547448A JP6266012B2 JP 6266012 B2 JP6266012 B2 JP 6266012B2 JP 2015547448 A JP2015547448 A JP 2015547448A JP 2015547448 A JP2015547448 A JP 2015547448A JP 6266012 B2 JP6266012 B2 JP 6266012B2
Authority
JP
Japan
Prior art keywords
antibody
hum13b8
shows
formulation
stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015547448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505572A (ja
JP2016505572A5 (enExample
Inventor
カシ，ラメシユ，エス
バドカー，アニケツト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6266012(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2016505572A publication Critical patent/JP2016505572A/ja
Publication of JP2016505572A5 publication Critical patent/JP2016505572A5/ja
Application granted granted Critical
Publication of JP6266012B2 publication Critical patent/JP6266012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015547448A 2012-12-13 2013-12-09 改変抗ＩＬ−２３ｐ１９抗体の溶液製剤 Active JP6266012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13
US61/737,035 2012-12-13
PCT/US2013/073825 WO2014093203A1 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2016505572A JP2016505572A (ja) 2016-02-25
JP2016505572A5 JP2016505572A5 (enExample) 2017-12-14
JP6266012B2 true JP6266012B2 (ja) 2018-01-24

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015547448A Active JP6266012B2 (ja) 2012-12-13 2013-12-09 改変抗ＩＬ−２３ｐ１９抗体の溶液製剤

Country Status (31)

Country Link
US (3) US20150329632A1 (enExample)
EP (1) EP2931313B1 (enExample)
JP (1) JP6266012B2 (enExample)
KR (1) KR102004585B1 (enExample)
CN (1) CN104870016B (enExample)
AU (1) AU2013359767B2 (enExample)
BR (1) BR112015013540B1 (enExample)
CA (1) CA2894869C (enExample)
CL (1) CL2015001608A1 (enExample)
CY (1) CY1121895T1 (enExample)
DK (1) DK2931313T3 (enExample)
EA (1) EA034616B1 (enExample)
ES (1) ES2732861T3 (enExample)
HR (1) HRP20191137T1 (enExample)
HU (1) HUE045668T2 (enExample)
IL (3) IL307581A (enExample)
LT (1) LT2931313T (enExample)
MX (1) MX357936B (enExample)
MY (1) MY187921A (enExample)
NZ (1) NZ708443A (enExample)
PE (1) PE20151524A1 (enExample)
PH (1) PH12015501296B1 (enExample)
PL (1) PL2931313T3 (enExample)
PT (1) PT2931313T (enExample)
RS (1) RS59057B1 (enExample)
SI (1) SI2931313T1 (enExample)
SM (1) SMT201900414T1 (enExample)
TR (1) TR201909584T4 (enExample)
UA (1) UA117466C2 (enExample)
WO (1) WO2014093203A1 (enExample)
ZA (1) ZA201504408B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025071362A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 안정한 액상 제형

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
WO2018181876A1 (ja) * 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
JP7637618B2 (ja) * 2018-11-21 2025-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度タンパク質製剤
AU2019386021B2 (en) 2018-11-27 2024-02-15 Innovent Biologics (Suzhou) Co., Ltd. Anti-il-23p19 antibody and uses thereof
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
EP3928101B1 (en) * 2019-02-20 2024-10-09 Amgen Inc. Methods of determining protein stability
EP3956357A4 (en) * 2019-04-15 2023-01-04 Sun Pharmaceutical Industries Limited METHODS OF TREATMENT OF SUBJECTS WITH PSORIAL ARTHRITIS
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
TW202535466A (zh) * 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CN115135671A (zh) * 2019-12-20 2022-09-30 新石生物制药有限公司 抗白介素-23 p19的抗体及其使用方法
CA3178853A1 (en) * 2020-05-13 2021-11-18 Wei Cao Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942114A3 (en) 1999-03-11 2008-08-27 Schering Corporation Mammalian cytokines; related reagents and methods
ATE389019T1 (de) 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
EP3777880A1 (en) 2003-02-10 2021-02-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
TWI357336B (en) 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
WO2004091658A1 (en) * 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
CN1942201B (zh) 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
JP4879884B2 (ja) 2004-04-12 2012-02-22 メディミューン，エルエルシー 抗−ｉｌ−９抗体製剤及びその使用法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
CA2619052A1 (en) 2005-08-25 2007-03-01 Eli Lily And Company Anti-il-23 antibiodies
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
RS58098B1 (sr) * 2007-02-23 2019-02-28 Merck Sharp & Dohme Anti-il-23p19 antitela proizvedena genetičkim inženjerstvom
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2205276A4 (en) 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
PL2234600T3 (pl) 2007-12-21 2015-02-27 Hoffmann La Roche Preparat przeciwciała
NZ589434A (en) * 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
ES2658596T3 (es) * 2008-09-19 2018-03-12 Pfizer Inc. Formulación líquida estable de anticuerpos
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
EP2822591B1 (en) * 2012-03-07 2018-05-02 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025071362A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 안정한 액상 제형

Also Published As

Publication number Publication date
IL239150B (en) 2020-11-30
ZA201504408B (en) 2017-09-27
DK2931313T3 (da) 2019-07-15
LT2931313T (lt) 2019-09-25
US20240239884A1 (en) 2024-07-18
KR20150092763A (ko) 2015-08-13
SMT201900414T1 (it) 2019-09-09
MY187921A (en) 2021-10-28
UA117466C2 (uk) 2018-08-10
HUE045668T2 (hu) 2020-01-28
EA201591133A1 (ru) 2015-10-30
AU2013359767A1 (en) 2015-07-23
BR112015013540B1 (pt) 2021-04-27
CL2015001608A1 (es) 2015-10-30
PL2931313T3 (pl) 2019-10-31
PH12015501296A1 (en) 2015-08-24
CN104870016A (zh) 2015-08-26
ES2732861T3 (es) 2019-11-26
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19
PH12015501296B1 (en) 2015-08-24
BR112015013540A8 (pt) 2018-04-17
IL307581A (en) 2023-12-01
JP2016505572A (ja) 2016-02-25
IL278295B2 (en) 2024-03-01
BR112015013540A2 (pt) 2017-11-14
WO2014093203A1 (en) 2014-06-19
US20210188964A1 (en) 2021-06-24
MX357936B (es) 2018-07-31
IL278295B1 (en) 2023-11-01
EP2931313A4 (en) 2016-08-03
CA2894869C (en) 2021-06-15
NZ708443A (en) 2018-05-25
HRP20191137T1 (hr) 2019-09-20
CY1121895T1 (el) 2020-10-14
IL278295A (enExample) 2020-12-31
TR201909584T4 (tr) 2019-07-22
AU2013359767B2 (en) 2018-04-05
EP2931313B1 (en) 2019-05-08
MX2015007213A (es) 2016-08-03
EP2931313A1 (en) 2015-10-21
RS59057B1 (sr) 2019-08-30
CN104870016B (zh) 2018-05-08
PE20151524A1 (es) 2015-11-06
CA2894869A1 (en) 2014-06-19
EA034616B1 (ru) 2020-02-27
SI2931313T1 (sl) 2019-09-30
HK1215194A1 (en) 2016-08-19
IL239150A0 (en) 2015-07-30
KR102004585B1 (ko) 2019-07-26

Similar Documents

Publication Publication Date Title
JP6266012B2 (ja) 改変抗ＩＬ−２３ｐ１９抗体の溶液製剤
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
RU2581812C2 (ru) Гуманизированные антитела против il-10 для лечения системной красной волчанки (sle)
JP2016028086A (ja) 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
CN103748110A (zh) 具有增加的FcRn结合的抗原结合蛋白
WO2020259605A1 (zh) 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
WO2022178159A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
JP2021503472A (ja) 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
TW202200203A (zh) 包含抗IL-23p19抗體的製劑、其製備方法和用途
TW202130367A (zh) 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途
WO2024173865A2 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
WO2024173838A2 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
WO2024173877A1 (en) Anti-tl1a antibody compositions and methods of treatment in the liver
CN119768431A (zh) Igf1r抗体
HK1215194B (en) Solution formulations of engineered anti-il-23p19 antibodies
WO2025221933A1 (en) Antibodies and polypeptides comprising variant fc regions
CN117202932A (zh) 治疗肺部的抗tl1a抗体组合物和方法
JP2022539088A (ja) 抗ｌａｇ‐３抗体を含む製剤、その調製方法及び使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20171031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171219

R150 Certificate of patent or registration of utility model

Ref document number: 6266012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250